Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs DISHMAN PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES DISHMAN PHARMA DIVIS LABORATORIES/
DISHMAN PHARMA
 
P/E (TTM) x 60.4 25.1 240.6% View Chart
P/BV x 13.9 3.3 415.7% View Chart
Dividend Yield % 0.4 0.7 66.1%  

Financials

 DIVIS LABORATORIES   DISHMAN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
DISHMAN PHARMA
Mar-16
DIVIS LABORATORIES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,639374 437.8%   
Low Rs1,115129 865.0%   
Sales per share (Unadj.) Rs186.3197.8 94.2%  
Earnings per share (Unadj.) Rs51.021.2 240.3%  
Cash flow per share (Unadj.) Rs57.334.7 165.1%  
Dividends per share (Unadj.) Rs16.002.00 800.0%  
Dividend yield (eoy) %1.20.8 146.2%  
Book value per share (Unadj.) Rs261.8179.9 145.5%  
Shares outstanding (eoy) m265.4780.69 329.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.41.3 581.0%   
Avg P/E ratio x27.011.9 227.7%  
P/CF ratio (eoy) x24.07.2 331.5%  
Price / Book Value ratio x5.31.4 376.1%  
Dividend payout %31.49.4 332.9%   
Avg Mkt Cap Rs m365,59220,306 1,800.4%   
No. of employees `00011.80.8 1,429.1%   
Total wages/salary Rs m5,4235,355 101.3%   
Avg. sales/employee Rs Th4,175.119,252.7 21.7%   
Avg. wages/employee Rs Th457.76,459.5 7.1%   
Avg. net profit/employee Rs Th1,141.82,064.1 55.3%   
INCOME DATA
Net Sales Rs m49,46315,961 309.9%  
Other income Rs m1,556265 586.4%   
Total revenues Rs m51,01916,226 314.4%   
Gross profit Rs m18,7184,103 456.2%  
Depreciation Rs m1,6891,091 154.9%   
Interest Rs m35944 3.7%   
Profit before tax Rs m18,5512,334 794.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023624 805.5%   
Profit after tax Rs m13,5271,711 790.6%  
Gross profit margin %37.825.7 147.2%  
Effective tax rate %27.126.7 101.3%   
Net profit margin %27.310.7 255.1%  
BALANCE SHEET DATA
Current assets Rs m46,50111,018 422.0%   
Current liabilities Rs m8,4689,517 89.0%   
Net working cap to sales %76.99.4 817.7%  
Current ratio x5.51.2 474.4%  
Inventory Days Days131110 118.4%  
Debtors Days Days8635 246.4%  
Net fixed assets Rs m25,79716,304 158.2%   
Share capital Rs m531161 328.9%   
"Free" reserves Rs m68,96212,907 534.3%   
Net worth Rs m69,49314,516 478.8%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m80,38329,805 269.7%  
Interest coverage x531.03.5 15,298.8%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.5 114.9%   
Return on assets %16.98.9 189.4%  
Return on equity %19.511.8 165.1%  
Return on capital %26.717.5 152.6%  
Exports to sales %024.8 0.0%   
Imports to sales %24.63.7 659.5%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs m12,187596 2,043.7%   
Fx inflow Rs m41,2384,952 832.8%   
Fx outflow Rs m12,405697 1,780.3%   
Net fx Rs m28,8334,255 677.7%   
CASH FLOW
From Operations Rs m9,5432,786 342.5%  
From Investments Rs m-6,854-1,529 448.3%  
From Financial Activity Rs m-2,459-941 261.3%  
Net Cashflow Rs m230316 72.6%  

Share Holding

Indian Promoters % 52.0 61.4 84.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 3.7 318.9%  
FIIs % 19.0 12.7 149.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 22.1 77.8%  
Shareholders   31,796 46,261 68.7%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  GLENMARK PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 15, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS